648 related articles for article (PubMed ID: 18061071)
21. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.
Vyas AK; Guo H; Moss AJ; Olshansky B; McNitt SA; Hall WJ; Zareba W; Steinberg JS; Fischer A; Ruskin J; Andrews ML;
J Am Coll Cardiol; 2006 Feb; 47(4):769-73. PubMed ID: 16487843
[TBL] [Abstract][Full Text] [Related]
22. QRS duration does not predict occurrence of ventricular tachyarrhythmias in patients with implanted cardioverter-defibrillators.
Buxton AE; Sweeney MO; Wathen MS; Josephson ME; Otterness MF; Hogan-Miller E; Stark AJ; Degroot PJ;
J Am Coll Cardiol; 2005 Jul; 46(2):310-6. PubMed ID: 16022960
[TBL] [Abstract][Full Text] [Related]
23. The dilemma of ICD implant testing.
Swerdlow CD; Russo AM; Degroot PJ
Pacing Clin Electrophysiol; 2007 May; 30(5):675-700. PubMed ID: 17461879
[TBL] [Abstract][Full Text] [Related]
24. Incidence of nonsustained and sustained ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.
Zhou X; Gunderson BD; Olson WH;
J Cardiovasc Electrophysiol; 2004 Jan; 15(1):14-20. PubMed ID: 15028067
[TBL] [Abstract][Full Text] [Related]
25. Clustering of ventricular tachyarrhythmias in heart failure patients implanted with a biventricular cardioverter defibrillator.
Lunati M; Gasparini M; Bocchiardo M; Curnis A; Landolina M; Carboni A; Luzzi G; Zanotto G; Ravazzi P; Magenta G; Denaro A; Distefano P; Grammatico A;
J Cardiovasc Electrophysiol; 2006 Dec; 17(12):1299-306. PubMed ID: 17239095
[TBL] [Abstract][Full Text] [Related]
26. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator.
Moss AJ; Greenberg H; Case RB; Zareba W; Hall WJ; Brown MW; Daubert JP; McNitt S; Andrews ML; Elkin AD;
Circulation; 2004 Dec; 110(25):3760-5. PubMed ID: 15583079
[TBL] [Abstract][Full Text] [Related]
27. Ventricular tachycardia or ventricular fibrillation occurs less often in patients with left bundle branch block and combined resynchronization and defibrillators than in patients with narrow QRS and conventional defibrillators.
Blaschke F; Knaus T; Celebi O; Krebs A; Nitardy A; Habedank D; Dietz R; Stockburger M
Europace; 2012 Feb; 14(2):224-9. PubMed ID: 21946820
[TBL] [Abstract][Full Text] [Related]
28. Right ventricular pacing is associated with impaired overall survival, but not with an increased incidence of ventricular tachyarrhythmias in routine cardioverter/defibrillator recipients with reservedly programmed pacing.
Stockburger M; Celebi O; Krebs A; Knaus T; Nitardy A; Habedank D; Dietz R
Europace; 2009 Jul; 11(7):924-30. PubMed ID: 19447808
[TBL] [Abstract][Full Text] [Related]
29. Baseline factors predicting early resumption of driving after life-threatening arrhythmias in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial.
Hickey K; Curtis AB; Lancaster S; Larsen G; Warwick D; McAnulty J; Mitchell LB
Am Heart J; 2001 Jul; 142(1):99-104. PubMed ID: 11431664
[TBL] [Abstract][Full Text] [Related]
30. Annual distribution of ventricular tachycardias and ventricular fibrillation.
Müller D; Lampe F; Wegscheider K; Schultheiss HP; Behrens S
Am Heart J; 2003 Dec; 146(6):1061-5. PubMed ID: 14660999
[TBL] [Abstract][Full Text] [Related]
31. Role of proinflammatory markers and NT-proBNP in patients with an implantable cardioverter-defibrillator and an electrical storm.
Streitner F; Kuschyk J; Veltmann C; Ratay D; Schoene N; Streitner I; Brueckmann M; Schumacher B; Borggrefe M; Wolpert C
Cytokine; 2009 Sep; 47(3):166-72. PubMed ID: 19604708
[TBL] [Abstract][Full Text] [Related]
32. Gender differences in ventricular arrhythmia recurrence in patients with coronary artery disease and implantable cardioverter-defibrillators.
Lampert R; McPherson CA; Clancy JF; Caulin-Glaser TL; Rosenfeld LE; Batsford WP
J Am Coll Cardiol; 2004 Jun; 43(12):2293-9. PubMed ID: 15193696
[TBL] [Abstract][Full Text] [Related]
33. Prevalence, predictors, and mortality significance of the causative arrhythmia in patients with electrical storm.
Verma A; Kilicaslan F; Marrouche NF; Minor S; Khan M; Wazni O; Burkhardt JD; Belden WA; Cummings JE; Abdul-Karim A; Saliba W; Schweikert RA; Tchou PJ; Martin DO; Natale A
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1265-70. PubMed ID: 15574176
[TBL] [Abstract][Full Text] [Related]
34. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study.
Steinberg JS; Martins J; Sadanandan S; Goldner B; Menchavez E; Domanski M; Russo A; Tullo N; Hallstrom A;
Am Heart J; 2001 Sep; 142(3):520-9. PubMed ID: 11526368
[TBL] [Abstract][Full Text] [Related]
35. Long-term outcome of patients who received implantable cardioverter defibrillators for stable ventricular tachycardia.
Glikson M; Lipchenca I; Viskin S; Ballman KV; Trusty JM; Gurevitz OT; Luria DM; Eldar M; Hammill SC; Friedman PA
J Cardiovasc Electrophysiol; 2004 Jun; 15(6):658-64. PubMed ID: 15175060
[TBL] [Abstract][Full Text] [Related]
36. Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial.
Zareba W; Daubert JP; Beck CA; Huang DT; Alexis JD; Brown MW; Pyykkonen K; McNitt S; Oakes D; Feng C; Aktas MK; Ayala-Parades F; Baranchuk A; Dubuc M; Haigney M; Mazur A; McPherson CA; Mitchell LB; Natale A; Piccini JP; Raitt M; Rashtian MY; Schuger C; Winters S; Worley SJ; Ziv O; Moss AJ;
J Am Coll Cardiol; 2018 Aug; 72(6):636-645. PubMed ID: 30071993
[TBL] [Abstract][Full Text] [Related]
37. Effect of programmed number of intervals to detect ventricular fibrillation on implantable cardioverter-defibrillator aborted and unnecessary shocks.
Gunderson BD; Abeyratne AI; Olson WH; Swerdlow CD
Pacing Clin Electrophysiol; 2007 Feb; 30(2):157-65. PubMed ID: 17338710
[TBL] [Abstract][Full Text] [Related]
38. Obesity as a risk factor for sustained ventricular tachyarrhythmias in MADIT II patients.
Pietrasik G; Goldenberg I; McNitt S; Moss AJ; Zareba W
J Cardiovasc Electrophysiol; 2007 Feb; 18(2):181-4. PubMed ID: 17338766
[TBL] [Abstract][Full Text] [Related]
39. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
Noseworthy PA; Rosenberg MA; Fifer MA; Palacios IF; Lowry PA; Ruskin JN; Sanborn DM; Picard MH; Vlahakes GJ; Mela T; Das S
Am J Cardiol; 2009 Jul; 104(1):128-32. PubMed ID: 19576333
[TBL] [Abstract][Full Text] [Related]
40. Hydroquinidine therapy in Brugada syndrome.
Hermida JS; Denjoy I; Clerc J; Extramiana F; Jarry G; Milliez P; Guicheney P; Di Fusco S; Rey JL; Cauchemez B; Leenhardt A
J Am Coll Cardiol; 2004 May; 43(10):1853-60. PubMed ID: 15145111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
